Skip to main content
Molecular & Cellular Proteomics

Main menu

  • Home
  • Articles
    • Current Issue
    • Papers in Press
    • Reviews and Minireviews
    • Special Issues
    • Editorials
    • Archive
    • Letters to the Editor (eLetters)
  • Info for
    • Authors
      • Editorial Policies
      • How to Submit
      • Manuscript Contents & Organization
      • Data Reporting Requirements
      • Publication Charges
    • Reviewers
    • Librarians
    • Advertisers
    • Subscribers
  • Guidelines
    • Proteomic Identification
      • Checklist (PDF)
      • Instructions for Annotated Spectra
      • Tutorial (PDF)
    • Clinical Proteomics
      • Checklist (PDF)
    • Glycomic Identification
      • Checklist (PDF)
    • Targeted Proteomics
      • Checklist (PDF)
    • Data-Independent Acquisition
      • Checklist (PDF)
    • Frequently Asked Questions
  • About
    • Mission Statement and Scope
    • Editorial Policies
    • Editorial Board
    • MCP Lectureships
    • Permissions and Licensing
    • Partners
    • Alerts
    • Contact Us

Submit

  • Submit
  • Publications
    • ASBMB
    • Molecular & Cellular Proteomics
    • Journal of Biological Chemistry
    • Journal of Lipid Research

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
  • Publications
    • ASBMB
    • Molecular & Cellular Proteomics
    • Journal of Biological Chemistry
    • Journal of Lipid Research
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Molecular & Cellular Proteomics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Papers in Press
    • Reviews and Minireviews
    • Special Issues
    • Editorials
    • Archive
    • Letters to the Editor (eLetters)
  • Info for
    • Authors
      • Editorial Policies
      • How to Submit
      • Manuscript Contents & Organization
      • Data Reporting Requirements
      • Publication Charges
    • Reviewers
    • Librarians
    • Advertisers
    • Subscribers
  • Guidelines
    • Proteomic Identification
      • Checklist (PDF)
      • Instructions for Annotated Spectra
      • Tutorial (PDF)
    • Clinical Proteomics
      • Checklist (PDF)
    • Glycomic Identification
      • Checklist (PDF)
    • Targeted Proteomics
      • Checklist (PDF)
    • Data-Independent Acquisition
      • Checklist (PDF)
    • Frequently Asked Questions
  • About
    • Mission Statement and Scope
    • Editorial Policies
    • Editorial Board
    • MCP Lectureships
    • Permissions and Licensing
    • Partners
    • Alerts
    • Contact Us
  • Submit

Assay development

  • Absolute Quantification of Apolipoproteins Following Treatment with Omega-3 Carboxylic Acids and Fenofibrate Using a High Precision Stable Isotope-labeled Recombinant Protein Fragments Based SRM Assay
    Open Access
    Absolute Quantification of Apolipoproteins Following Treatment with Omega-3 Carboxylic Acids and Fenofibrate Using a High Precision Stable Isotope-labeled Recombinant Protein Fragments Based SRM Assay
    Andreas Hober, Fredrik Edfors, Maria Ryaboshapkina, Jonas Malmqvist, Louise Rosengren, Andrew J. Percy, Lars Lind, Björn Forsström, Mathias Uhlén, Jan Oscarsson and Tasso Miliotis
    Molecular & Cellular Proteomics December 1, 2019, First published on October 7, 2019, 18 (12) 2433-2446; https://doi.org/10.1074/mcp.RA119.001765

    Applications of LC-SRM in clinical research are still limited. SIS PrEST are a novel class of standards added prior to trypsinization. We have developed a semi-automated sample preparation workflow and a SIS PrEST LC-SRM/MS Tier 2 assay for absolute quantification of 13 apolipoproteins in human plasma and applied it on clinical samples from the EFFECT I study. We demonstrate, for the first time, that SIS PrEST can be applied for exploratory biomarker research in clinical settings and capture drug effects.

  • A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155
    You have access
    A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155
    Bushra Husain, Sree R. Ramani, Eugene Chiang, Isabelle Lehoux, Sairupa Paduchuri, Tia A. Arena, Ashka Patel, Blair Wilson, Pamela Chan, Yvonne Franke, Athena W. Wong, Jennie R. Lill, Shannon J. Turley, Lino C. Gonzalez, Jane L. Grogan and Nadia Martinez-Martin
    Molecular & Cellular Proteomics November 1, 2019, First published on July 15, 2019, 18 (11) 2310-2323; https://doi.org/10.1074/mcp.TIR119.001433

    The Conditioned Media AlphaScreen represents a new platform for high throughput and sensitivity detection of interactions between plasma membrane proteins. The interleukin receptor IL20RA is identified as a binding partner for the orphan checkpoint inhibitor B7-H3. Further, a new functional interaction between the KIR2DL5 and the immune receptor PVR regulates natural killer cell cytolysis of tumor cells. This technology represents a versatile approach for receptor interactome discovery that provides insights into plasma membrane protein biology.

  • Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients
    You have access
    Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients
    Andrei P. Drabovich, Punit Saraon, Mikalai Drabovich, Theano D. Karakosta, Apostolos Dimitromanolakis, M. Eric Hyndman, Keith Jarvi and Eleftherios P. Diamandis
    Molecular & Cellular Proteomics September 1, 2019, First published on June 27, 2019, 18 (9) 1807-1823; https://doi.org/10.1074/mcp.RA119.001612

    Multi-omics biomarker pipeline generated 19 proteins which were verified by a multiplex quantitative SRM assay in seminal plasma samples of 152 prostate cancer and 67 negative biopsy patients. Verification revealed a prostate-specific, secreted and androgen-regulated protein-glutamine gamma-glutamyltransferase 4 (TGM4), which detected prostate cancer on biopsies with AUC=0.66, as measured by an in-house immunoassay in seminal plasma. Perspectives of seminal plasma proteins as biomarkers of prostate cancer were reviewed.

  • Intact Transition Epitope Mapping – Targeted High-Energy Rupture of Extracted Epitopes (ITEM-THREE)
    You have access
    Intact Transition Epitope Mapping – Targeted High-Energy Rupture of Extracted Epitopes (ITEM-THREE)
    Bright D. Danquah, Claudia Röwer, Kwabena F. M. Opuni, Reham El-Kased, David Frommholz, Harald Illges, Cornelia Koy and Michael O. Glocker
    Molecular & Cellular Proteomics August 1, 2019, First published on May 30, 2019, 18 (8) 1543-1555; https://doi.org/10.1074/mcp.RA119.001429

    ITEM-THREE enables rapid epitope mapping. Sample consumption is minimized and in-solution handling reduced to mixing of antibody and antigen peptide solutions. After immune complex formation in solution, epitope mapping is performed in the gas phase using the mass spectrometer for sophisticated ion manipulation and filtering. Because amino acid sequence information is obtained from the epitope peptide, unknown antigens can be identified. Knowing the epitope broadens the application of antibodies to unspecified target proteins from any organism.

  • High-throughput Identification of FLT3 Wild-type and Mutant Kinase Substrate Preferences and Application to Design of Sensitive <em>In Vitro</em> Kinase Assay Substrates
    You have access
    High-throughput Identification of FLT3 Wild-type and Mutant Kinase Substrate Preferences and Application to Design of Sensitive In Vitro Kinase Assay Substrates
    Minervo Perez, John Blankenhorn, Kevin J. Murray and Laurie L. Parker
    Molecular & Cellular Proteomics March 1, 2019, First published on December 12, 2018, 18 (3) 477-489; https://doi.org/10.1074/mcp.RA118.001111

    Kinase activity assays are an invaluable tool used to develop new small molecule inhibitors to combat cancer and other human diseases, however, only a small fraction of the human kinome is well characterized. Lack of biological substrate information limits the capability of computational approaches to design sensitive peptide probes for FLT3 and clinically relevant mutant kinases. In this report, we used phosphoproteomics and the KINATEST-ID pipeline (31) to design a panel of FLT3 artificial peptide substrates (FAStides) to design an ELISA-based activity assay.

  • Follow MCP on Twitter
  • RSS feeds
  • Email

Articles

  • Current Issue
  • Papers in Press
  • Archive

For Authors

  • Submit a Manuscript
  • Info for Authors

Guidelines

  • Proteomic Identification
  • Clinical Proteomics
  • Glycomic Identification
  • Targeted Proteomics
  • Frequently Asked Questions

About MCP

  • About the Journal
  • Permissions and Licensing
  • Advertisers
  • Subscribers

ASBMB Publications

  • Molecular & Cellular Proteomics
  • Journal of Biological Chemistry
  • Journal of Lipid Research
  • ASBMB Today

© 2019 American Society for Biochemistry and Molecular Biology | Privacy Policy

MCP Print ISSN 1535-9476 Online ISSN 1535-9484

Powered by HighWire